Skip to main content

Cookies on the NHS England website

We’ve put some small files called cookies on your device to make our site work.

We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.

Let us know if this is OK. We’ll use a cookie to save your choice. You canĀ read more about our cookies before you choose.

 

Your feedback matters and will make a difference. Help us understand your digital experience by taking our 10 minute survey. Your responses are completely anonymous. Start the survey.

  • Home
  • News
  • Publications
  • Statistics
  • Blogs
  • Events
  • Contact us
NHS England
  • About us
  • Our work
  • Commissioning
  • Get involved

Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

Document first published:
9 July 2020
Page updated:
22 July 2020
Topic:
Commissioning, Medicine, Specialised commissioning
Publication type:
Policy or strategy, Report

Document

Clinical commissioning policy: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

Clinical commissioning policy: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

  • PDF
  • 206 KB
  • 12 pages

Document

Clinical panel report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

Clinical panel report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

  • PDF
  • 23 KB
  • 2 pages

Document

CPAG summary report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

CPAG summary report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

  • PDF
  • 145 KB
  • 11 pages

Document

Evidence report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

Evidence report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

  • PDF
  • 56 KB
  • 2 pages

Document

Evidence report 2: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

Evidence report 2: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

  • PDF
  • 20 KB
  • 2 pages

Document

Evidence review: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

Evidence review: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

  • PDF
  • 704 KB
  • 35 pages

Document

Public consultation report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

Public consultation report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

  • PDF
  • 87 KB
  • 6 pages

Document

Public engagement report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

Public engagement report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

  • PDF
  • 43 KB
  • 3 pages
  • Terms and conditions
  • Privacy and cookies
  • Social media moderation
  • Website feedback
  • Accessibility statement
  • Open Government Licence v3.0
  • Sign up to our email bulletins
  • Follow us on X
  • Follow us on Facebook
  • Find us on Instagram
  • Visit us on LinkedIn
  • Watch videos on YouTube
NHS website